Identification and selective depletion of alloreactive T-cells for adoptive immunotherapy.

BACKGROUND T-cell-depleted allografts may exhibit delayed T-cell recovery, severe infections, and relapse after haploidentical hematopoietic stem cell transplantation (HSCT). Required donor lymphocyte infusions containing nonalloreactive cells may transfer immune function without causing graft-versus-host disease. METHODS We developed an ex vivo approach for the immunomagnetic depletion of alloreactive CD25+, CD69+, and HLA-DR+ T-cells. To achieve highest rates of alloantigen expression, we cocultured peripheral blood mononuclear cells (PBMNCs) with PBMNCs (A/B*), dendritic cells (A/B* DCs), or cytokine-pretreated PBMNCs (A/B* cyt cells). Functional analyses were performed after depletion. RESULTS After coculture with PBMNCs (A/B* cells), 29% of T-cells became CD25+, CD69+, and HLA-DR+. In modified mixed lymphocyte reactions (MLR) (A/B* cyt cells and A/B* DCs), 35% and 37% of T-cells became CD25+, CD69+, and HLA-DR+. Alloactivation was confirmed by interferon gamma release and proliferation. Immuno-magnetic depletion produced <1% alloactivated cells. Furthermore, this depletion strategy was allospecific and hardly impaired the immune function of the retained cells. DISCUSSION The efficiency of immunomagnetic depletion depended on the stimulatory capacity of stimulator cells and was improved by using cytokine-pretreated PBMNCs for alloactivation. Overall, this approach might be a promising strategy for restoration of the immune system, particularly after haploidentical HSCT.

[1]  A. Ganser,et al.  Infusion of suicide-gene-engineered donor lymphocytes after family haploidentical haemopoietic stem-cell transplantation for leukaemia (the TK007 trial): a non-randomised phase I-II study. , 2009, The Lancet. Oncology.

[2]  R. Handgretinger,et al.  Molecular monitoring of immune reconstitution after haploidentical stem cell transplantation. , 2008, Current stem cell research & therapy.

[3]  T. Klingebiel,et al.  T cells for suicide gene therapy: activation, functionality and clinical relevance. , 2008, Journal of immunological methods.

[4]  R. Handgretinger,et al.  Cellular immune reconstitution after haploidentical transplantation in children. , 2008, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[5]  R. Handgretinger,et al.  Feasibility and Outcome of Reduced‐Intensity Conditioning in Haploidentical Transplantation , 2007, Annals of the New York Academy of Sciences.

[6]  Shamsul A. Khan,et al.  Targeting the activation-induced antigen CD137 can selectively deplete alloreactive T cells from antileukemic and antitumor donor T-cell lines. , 2007, Blood.

[7]  R. Krance,et al.  Adoptive immunotherapy with allodepleted donor T-cells improves immune reconstitution after haploidentical stem cell transplantation. , 2006, Blood.

[8]  C. Huber,et al.  Depletion of alloreactive T cells via CD69: implications on antiviral, antileukemic and immunoregulatory T lymphocytes , 2006, Bone Marrow Transplantation.

[9]  A. Barrett,et al.  Selective depletion of alloreactive donor lymphocytes: a novel method to reduce the severity of graft-versus-host disease in older patients undergoing matched sibling donor stem cell transplantation. , 2005, Blood.

[10]  T. Klingebiel,et al.  Experiences with haploidentical stem cell transplantation in children with acute lymphoblastic leukemia. , 2005, Pathologie-biologie.

[11]  J. Hansen T-cell alloreactivity in hematopoietic stem cell transplantation. , 2005, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[12]  R. Champlin,et al.  Functional assessment and specific depletion of alloreactive human T cells using flow cytometry. , 2004, Blood.

[13]  T. Klingebiel,et al.  Haploidentical transplantation for acute lymphoblastic leukemia in childhood. , 2004, Blood reviews.

[14]  B. Blazar,et al.  Ex vivo depletion of alloreactive cells based on CFSE dye dilution, activation antigen selection, and dendritic cell stimulation. , 2004, Blood.

[15]  J. Gorski,et al.  Selective elimination of alloreactive donor T cells attenuates graft-versus-host disease and enhances T-cell reconstitution. , 2003, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[16]  J. Michálek,et al.  Selective depletion of donor alloreactive T cells without loss of antiviral or antileukemic responses. , 2003, Blood.

[17]  T. Klingebiel,et al.  Megadose transplantation of highly purified haploidentical stem cells: current results and future prospects , 2003, Pediatric transplantation.

[18]  C. Perreault,et al.  P-glycoprotein targeting: a unique strategy to selectively eliminate immunoreactive T cells. , 2002, Blood.

[19]  A. Fischer,et al.  Immune reconstitution without graft-versus-host disease after haemopoietic stem-cell transplantation: a phase 1/2 study , 2002, The Lancet.

[20]  N. Chao,et al.  Prevention of graft-versus-host disease while preserving graft-versus-leukemia effect after selective depletion of host-reactive T cells by photodynamic cell purging process. , 2002, Blood.

[21]  C. Huber,et al.  Murine acute graft-versus-host disease can be prevented by depletion of alloreactive T lymphocytes using activation-induced cell death. , 2002, Blood.

[22]  A. Hagenbeek,et al.  Elimination of the truncated message from the herpes simplex virus thymidine kinase suicide gene. , 2001, Molecular therapy : the journal of the American Society of Gene Therapy.

[23]  T. Klingebiel,et al.  Megadose transplantation of purified peripheral blood CD34+progenitor cells from HLA-mismatched parental donors in children , 2001, Bone Marrow Transplantation.

[24]  E. Palmer,et al.  Quantifying the Frequency of Alloreactive T Cells In Vivo: New Answers to an Old Question1 , 2001, The Journal of Immunology.

[25]  A. Zander,et al.  Efficient depletion of alloreactive donor T lymphocytes based on expression of two activation‐induced antigens (CD25 and CD69) , 2000, British journal of haematology.

[26]  B. Fehse,et al.  Depletion of alloreactive donor T cells using immunomagnetic cell selection , 2000, Bone Marrow Transplantation.

[27]  L. Verdonck,et al.  Selective depletion of major and minor histocompatibility antigen reactive T cells: towards prevention of acute graft‐versus‐host disease , 1999, British journal of haematology.

[28]  J. Gribben,et al.  Transplantation of anergic histoincompatible bone marrow allografts. , 1999, The New England journal of medicine.

[29]  V. Calcaterra,et al.  Depletion of alloreactive T cells by a specific anti-interleukin-2 receptor p55 chain immunotoxin does not impair in vitro antileukemia and antiviral activity. , 1999, Blood.

[30]  H. Prentice,et al.  Selective removal of alloreactive cells from haematopoietic stem cell grafts: graft engineering for GVHD prophylaxis , 1999, Bone Marrow Transplantation.

[31]  T. Klingebiel,et al.  Transplantation of Megadoses of Purified Haploidentical Stem Cells , 1999, Annals of the New York Academy of Sciences.

[32]  F. Marini,et al.  Effective depletion of alloreactive lymphocytes from peripheral blood mononuclear cell preparations. , 1999, Transplantation.

[33]  N. Flomenberg,et al.  Association of donor-derived host-reactive cytolytic and helper T cells with outcome following alternative donor T cell-depleted bone marrow transplantation , 1997, Bone Marrow Transplantation.

[34]  A. Balsari,et al.  Flow cytometric analysis of activation markers on stimulated T cells and their correlation with cell proliferation. , 1997, Cytometry.

[35]  J. Hurwitz,et al.  Eliminating graft-versus-host potential from T cell immunotherapeutic populations. , 1996, Bone marrow transplantation.

[36]  J. Gribben,et al.  Complete blockade of B7 family-mediated costimulation is necessary to induce human alloantigen-specific anergy: a method to ameliorate graft-versus-host disease and extend the donor pool. , 1996, Blood.

[37]  I. Pastan,et al.  Specific depletion of alloreactivity against haplotype mismatched related individuals by a recombinant immunotoxin: a new approach to graft-versus-host disease prophylaxis in haploidentical bone marrow transplantation. , 1996, Bone marrow transplantation.

[38]  E. Kedar,et al.  Prediction by a modified mixed leukocyte reaction assay of graft-versus-host disease and graft rejection after allogeneic bone marrow transplantation. , 1994, Transplantation.

[39]  A. Fischer,et al.  Attenuation of graft-versus-host disease and graft rejection by ex vivo immunotoxin elimination of alloreactive T cells in an H-2 haplotype disparate mouse combination. , 1994, Blood.

[40]  H. Rammensee,et al.  On the nature of peptides involved in T cell alloreactivity , 1991, The Journal of experimental medicine.

[41]  M. Ritter,et al.  Frequency analysis of cytotoxic T lymphocyte precursors--possible relevance to HLA-matched unrelated donor bone marrow transplantation. , 1988, Bone marrow transplantation.

[42]  W. Herzog,et al.  Human Cytotoxic T Lymphocytes , 1985, Scandinavian journal of immunology.